Want to see JP:4891 full AI Analyst Report?
Top Page
TMS Co., Ltd.
(4891)
Select Model
Select Model
Rating:53Neutral
Price Target:
¥134.00
▲(3.88% Upside)
Action:Reiterated
Date:09/20/26
Overall score is held back primarily by weak financial performance (multi-year losses and sustained cash burn), partially offset by a low-leverage balance sheet. Technicals are supportive with a clear uptrend, but overbought signals raise near-term risk. Valuation provides limited support due to negative earnings and no dividend data.
Positive Factors
No reported debt
The absence of reported debt reduces interest obligations and refinancing exposure, giving the company more balance-sheet flexibility than a similarly loss-making business with leverage. This cushion can help preserve strategic options while management works to improve commercial performance.
Negative Factors
Persistent operating losses
Multiple consecutive years of deep losses and effectively absent recent revenue indicate that the business is not currently demonstrating a recurring commercial engine. Without a dependable revenue base, earnings visibility remains weak and future progress depends heavily on successful business development or product outcomes.
Read all positive and negative factors
Positive Factors
Negative Factors
No reported debt
The absence of reported debt reduces interest obligations and refinancing exposure, giving the company more balance-sheet flexibility than a similarly loss-making business with leverage. This cushion can help preserve strategic options while management works to improve commercial performance.
Read all positive factors
TMS Co., Ltd. (4891) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥5.91B
Dividend YieldN/A
Average Volume (3M)413.51K
Price to Earnings (P/E)―
Beta (1Y)0.44
Revenue GrowthN/A
EPS GrowthN/A
CountryJP
Employees18
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-16.99
Shares Outstanding48,455,270
10 Day Avg. Volume329,260
30 Day Avg. Volume413,513
Financial Highlights & Ratios
PEG Ratio-0.37
Price to Book (P/B)2.07
Price to Sales (P/S)0.00
P/FCF Ratio-7.34
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-25.28
Revenue Forecast (FY)N/A
TMS Co., Ltd. Business Overview & Revenue Model
Company Description
Established in 2005 and headquartered in Fuchu, Japan, TMS Co., Ltd. focuses on the research, development, manufacturing, and commercialization of pharmaceuticals, quasi-drugs, drug substances, medical devices, and various medical commodities. The...
TMS Co., Ltd. Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Feb 2025 | Feb 2024 | Feb 2023 | Feb 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.95B |
| Gross Profit | -501.00K | -314.40K | -3.71M | -6.95M | -6.60M | 1.74B |
| EBITDA | -1.03B | -836.05M | -655.89M | -937.00M | -513.55M | 1.14B |
| Net Income | -699.20M | -859.27M | -660.55M | -960.04M | -860.92M | 1.08B |
Balance Sheet | ||||||
| Total Assets | 3.21B | 2.87B | 3.03B | 3.55B | 3.79B | 2.74B |
| Cash, Cash Equivalents and Short-Term Investments | 3.18B | 2.78B | 2.92B | 3.45B | 3.58B | 2.60B |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 122.98M | 95.00M | 216.78M | 97.69M | 76.16M | 286.78M |
| Stockholders Equity | 3.09B | 2.77B | 2.82B | 3.46B | 3.71B | 2.45B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | -782.43M | -524.60M | -826.17M | -702.14M | 1.25B |
| Operating Cash Flow | 0.00 | -779.89M | -493.76M | -822.81M | -688.42M | 1.26B |
| Investing Cash Flow | 0.00 | -2.54M | -30.84M | -3.36M | -13.72M | -16.96M |
| Financing Cash Flow | 0.00 | 640.52M | 919.00K | 688.13M | 1.69B | 246.48M |
TMS Co., Ltd. Technical Analysis
Negative
129.00
Price Trends
113.38
Positive
113.83
Positive
128.41
Negative
Market Momentum
3.50
Positive
49.12
Neutral
20.95
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4891, the sentiment is Negative. The current price of 129 is above the 20-day moving average (MA) of 126.80, above the 50-day MA of 113.38, and above the 200-day MA of 128.41, indicating a neutral trend. The MACD of 3.50 indicates Positive momentum. The RSI at 49.12 is Neutral, neither overbought nor oversold. The STOCH value of 20.95 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4891.
TMS Co., Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | ¥7.64B | 51.20 | ― | 1.51% | 4.85% | -40.57% | |
53 Neutral | ¥5.91B | -6.16 | ― | ― | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | ¥40.93B | 60.89 | ― | ― | -47.32% | ― | |
44 Neutral | ¥13.51B | -28.32 | ― | ― | -18.71% | -246.54% | |
44 Neutral | ¥8.34B | -7.29 | ― | ― | -56.16% | 3.12% | |
40 Underperform | ¥10.28B | -5.52 | ― | ― | ― | 4.68% |
* Healthcare Sector Average
JP:4891
TMS Co., Ltd.
122.00
-29.00
-19.21%
JP:4593
Healios KK
302.00
-166.00
-35.47%
JP:4599
StemRIM Inc.
164.00
-125.00
-43.25%
JP:4978
ReproCELL Inc.
130.00
-45.00
-25.71%
JP:7096
StemCell Institute
746.00
-133.00
-15.13%
JP:7776
CellSeed Inc.
211.00
-255.00
-54.72%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.